Login / Signup
Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.
D Dutzer
Y Nasser
A E Berger
Xavier Roblin
Stephane Paul
Published in:
Alimentary pharmacology & therapeutics (2019)
Keyphrases
</>
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
ulcerative colitis
single cell